Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Deferred Taxes (2016 - 2025)

Sangamo Therapeutics has reported Deferred Taxes over the past 5 years, most recently at $15000.0 for Q1 2025.

  • Quarterly results put Deferred Taxes at $15000.0 for Q1 2025, changed N/A from a year ago — trailing twelve months through Mar 2025 was $15000.0 (down 64.29% YoY), and the annual figure for FY2023 was -$6.3 million, changed.
  • Deferred Taxes for Q1 2025 was $15000.0 at Sangamo Therapeutics, up from -$18000.0 in the prior quarter.
  • Over the last five years, Deferred Taxes for SGMO hit a ceiling of $182000.0 in Q3 2023 and a floor of -$140000.0 in Q4 2023.
  • Median Deferred Taxes over the past 3 years was $15000.0 (2025), compared with a mean of $11400.0.
  • Peak annual rise in Deferred Taxes hit 87.14% in 2024, while the deepest fall reached 90.11% in 2024.
  • Sangamo Therapeutics' Deferred Taxes stood at -$140000.0 in 2023, then soared by 87.14% to -$18000.0 in 2024, then soared by 183.33% to $15000.0 in 2025.
  • The last three reported values for Deferred Taxes were $15000.0 (Q1 2025), -$18000.0 (Q4 2024), and $18000.0 (Q3 2024) per Business Quant data.